AR and prostate carcinoma: -AR-negative castration-resistant prostate cancer cell line (CRPC) as topoisomerase II catalytic inhibitor (88.9% growth inhibition at 20 μM) and by intercalating and binding to the DNA minor groove (IC50 = 0.13 ± 0.007 μM).-Sensitizes AR-positive CRPC cells to enzalutamide and taxanes.